65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, '65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016', provides in depth analysis on 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted pipeline therapeutics. 

The report provides comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
- The report reviews 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics and enlists all their major and minor projects 
- The report assesses 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Overview 6
Therapeutics Development 7
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Stage of Development 7
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Therapy Area 8
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Indication 9
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Companies 12
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Universities/Institutes 14
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Companies Involved in Therapeutics Development 21
Astellas Pharma Inc. 21
Atara Biotherapeutics, Inc. 22
Immunomic Therapeutics, Inc. 23
Vakzine Projekt Management GmbH 24
Vical Incorporated 25
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Drug Profiles 26
Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ASP-0113 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
CyMVectin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Cytomegalovirus vaccine 1 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
pp65 DC + Td - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
VPM-2001 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Dormant Projects 40
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Discontinued Products 41
65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Featured News & Press Releases 42
Dec 06, 2015: Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes, a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System 42
Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 2015 42
May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients 43
Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference 44
Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients 44
Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine 45
Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical 45
Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine 46
Jan 11, 2012: Vical Announces Online Publication Of Phase II Proof-Of-Concept Trial Results Of TransVax 46
Jul 14, 2011: Vical Announces Scientific Advances On CyMVectin At DNA Vaccines 2011 Conference 47
Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference 47
May 19, 2011: Vical To Present TransVax And DNA Vaccines At ASGCT Conference 47
Apr 14, 2011: Vical Receives Key European Patent For TransVax Cytomegalovirus Vaccine 48
Mar 02, 2011: Vical Receives Positive Scientific Advice From EMA For TransVax Phase III Trial 48
Sep 13, 2010: Vical Announces Positive Results From Phase II Trial Of TransVax CMV Vaccine 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Astellas Pharma Inc., H1 2016 21
Pipeline by Atara Biotherapeutics, Inc., H1 2016 22
Pipeline by Immunomic Therapeutics, Inc., H1 2016 23
Pipeline by Vakzine Projekt Management GmbH, H1 2016 24
Pipeline by Vical Incorporated, H1 2016 25
Dormant Projects, H1 2016 40
Discontinued Products, H1 2016 41